Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses …
Post
-
-
Omnipod 5 improves glycaemic levels in people transitioning from daily injections
Individuals with type 1 diabetes (T1D) have demonstrated improvements in glycaemic control after transitioning away from daily insulin injections to …
-
NACE to launch trial in Australia for young people with hay fever
The National Allergy Centre of Excellence (NACE), hosted at Murdoch Children's Research Institute (MCRI), has collaborated with 17 Australian general …
-
Funding drought: how can biotech and biopharma keep trials running?
It’s widely known in the industry that private investment in biotech and biopharma has been down in recent years. Whilst …
-
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset
Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight Family …
-
Omnipod 5 improves glycaemic levels in people transitioning from daily injections
Individuals with type 1 diabetes (T1D) have demonstrated improvements in glycaemic control after transitioning away from daily insulin injections to …
-
NACE to launch trial in Australia for young people with hay fever
The National Allergy Centre of Excellence (NACE), hosted at Murdoch Children's Research Institute (MCRI), has collaborated with 17 Australian general …
-
Funding drought: how can biotech and biopharma keep trials running?
It’s widely known in the industry that private investment in biotech and biopharma has been down in recent years. Whilst …
-
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset
Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight Family …
-
Novartis reports Phase III efficacy and safety outcomes of SMA treatment
Novartis has reported positive efficacy and safety outcomes from its Phase III clinical programme for OAV101 IT (onasemnogene abeparvovec), an …
-
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old
Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study (NCT05693142), which is examining …
-
Flatiron and NRG Oncology to deploy EHR-to-EDC technology in multi-centre trial
Flatiron Health has announced a partnership with NRG Oncology to implement the electronic health record (EHR) to electronic data capture …
-
Immunovant will not seek approval for MG therapy, despite hitting endpoints
Immunovant has decided not to seek regulatory approval for its myasthenia gravis (MG) therapy, batoclimab, despite the Phase III study …
-
Evinova and QLHC agree to incorporate RPM solution in breast cancer therapy trial
Healthcare technology company Evinova has entered an agreement with Quantum Leap Healthcare Collaborative (QLHC) to incorporate its remote patient monitoring …
-
High menopausal symptom burden linked to increased dementia risk
According to the World Health Organization (WHO), more than 55 million people have dementia globally. Though the major risk factor …
